Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


04.06.2018

5 Ann Thorac Surg
9 Anticancer Res
2 Arch Bronconeumol
2 BMC Cancer
1 Br J Cancer
1 Cancer Sci
1 Chest
8 Clin Lung Cancer
3 Clin Nucl Med
3 Eur Respir J
2 Int J Oncol
2 J Cancer Res Clin Oncol
1 J Clin Oncol
7 J Thorac Oncol
1 Lung Cancer
1 Lung Cancer (Auckl)
1 Mol Carcinog
1 N Engl J Med
1 Nat Med
3 Oncol Rep
1 PLoS Comput Biol
6 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. BRANDT WS, Yan W, Leeman JE, Tan KS, et al
    Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2018 May 25. pii: S0003-4975(18)30709.
    PubMed     Text format     Abstract available

  2. DRAKE JA, Portnoy DC, Tauer K, Weksler B, et al
    Adding Radiation to Adjuvant Chemotherapy Does Not Improve Survival of Patients with N2 Lung Cancer.
    Ann Thorac Surg. 2018 May 29. pii: S0003-4975(18)30720.
    PubMed     Text format     Abstract available

  3. JIANG XH, Yie SM
    Clarification needed regarding anti-topoisomerase I as a biomarker for non-small cell lung cancer (Reply).
    Ann Thorac Surg. 2018 May 29. pii: S0003-4975(18)30724.
    PubMed     Text format    

  4. YANG X, Zhan C, Li M, Huang Y, et al
    Lobectomy versus Sublobectomy in Metachronous Second Primary Lung Cancer: A Propensity-Score Study.
    Ann Thorac Surg. 2018 May 28. pii: S0003-4975(18)30716.
    PubMed     Text format     Abstract available

  5. SHOJI F, Takeo S, Yamazaki K, Miura N, et al
    Impact of Preoperative Ultrasonography Screening For Carotid Artery Stenosis in Lung Cancer Patients.
    Ann Thorac Surg. 2018 May 28. pii: S0003-4975(18)30718.
    PubMed     Text format     Abstract available


    Anticancer Res

  6. RAUNGRUT P, Wongkotsila A, Champoochana N, Lirdprapamongkol K, et al
    Knockdown of 14-3-3gamma Suppresses Epithelial-Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:3507-3514.
    PubMed     Text format     Abstract available

  7. MATSUMOTO T, Hasebe T, Baba Y, Chosa K, et al
    Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3587-3592.
    PubMed     Text format     Abstract available

  8. BANNA GL, Camerini A, Bronte G, Anile G, et al
    Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Anticancer Res. 2018;38:3689-3697.
    PubMed     Text format     Abstract available

  9. TOYOKAWA G, Takada K, Tagawa T, Kinoshita F, et al
    Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:3707-3711.
    PubMed     Text format     Abstract available

  10. TAKAMORI S, Toyokawa G, Shimokawa M, Kinoshita F, et al
    Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Anticancer Res. 2018;38:3731-3734.
    PubMed     Text format     Abstract available

  11. SYRIGOS KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, et al
    Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.
    Anticancer Res. 2018;38:3735-3744.
    PubMed     Text format     Abstract available

  12. SHOJI F, Yamazaki K, Miura N, Katsura M, et al
    Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3773-3778.
    PubMed     Text format     Abstract available

  13. TAKEOKA H, Yamada K, Naito Y, Matsuo N, et al
    Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Anticancer Res. 2018;38:3779-3784.
    PubMed     Text format     Abstract available

  14. KOYI H, Branden E, Kasim I, Wilander E, et al
    Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3341-3346.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  15. GOROSPE-SARASUA L, Eugenia-Rioja M, Ajuria-Illarramendi O, Cabanero-Sanchez A, et al
    Percutaneous Marking of 2Adjacent Pulmonary Metastases With a Single Equidistant Seed.
    Arch Bronconeumol. 2018 May 23. pii: S0300-2896(18)30166.
    PubMed     Text format    

  16. BREA TP, Ravina AR, Villamor JMC, Gomez AG, et al
    Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review.
    Arch Bronconeumol. 2018 May 23. pii: S0300-2896(18)30149.
    PubMed     Text format     Abstract available


    BMC Cancer

  17. MARINGE C, Pashayan N, Rubio FJ, Ploubidis G, et al
    Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?
    BMC Cancer. 2018;18:615.
    PubMed     Text format     Abstract available

  18. ZENG J, Zhang H, Tan Y, Sun C, et al
    Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:611.
    PubMed     Text format     Abstract available


    Br J Cancer

  19. ABOU FAYCAL C, Brambilla E, Agorreta J, Lepeltier N, et al
    The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0128.
    PubMed     Text format     Abstract available


    Cancer Sci

  20. AZUMA K, Nishio M, Hayashi H, Kiura K, et al
    ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.
    Cancer Sci. 2018 May 28. doi: 10.1111/cas.13651.
    PubMed     Text format     Abstract available


    Chest

  21. ROJEWSKI AM, Tanner NT, Dai L, Ravenel JG, et al
    Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial.
    Chest. 2018 May 17. pii: S0012-3692(18)30587-7. doi: 10.1016/j.chest.2018.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  22. FUJIMOTO D, Sato Y, Morimoto T, Uehara K, et al
    Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30094.
    PubMed     Text format     Abstract available

  23. LOONG HH, Raymond VM, Shiotsu Y, Chua DTT, et al
    Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30104.
    PubMed     Text format     Abstract available

  24. ZER A, Sung MR, Walia P, Khoja L, et al
    Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 May 8. pii: S1525-7304(18)30090.
    PubMed     Text format     Abstract available

  25. GINESTET F, Lambros L, Le Flahec G, Marcorelles P, et al
    Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30098.
    PubMed     Text format     Abstract available

  26. FACCHINETTI F, Gnetti L, Caruana P, Fornaroli F, et al
    Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30095.
    PubMed     Text format    

  27. LAMBROS L, Uguen A
    Toward a Molecular Diagnosis in a Single Day for Patients With Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30044.
    PubMed     Text format    

  28. VANDERLAAN PA, Chen Y, DiStasio M, Rangachari D, et al
    Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
    Clin Lung Cancer. 2018 May 4. pii: S1525-7304(18)30087.
    PubMed     Text format    

  29. FUKUI T, Okuma Y, Nakahara Y, Otani S, et al
    Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
    Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30103.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  30. ESHGHI N, Lundeen TF, Kuo PH
    Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.
    Clin Nucl Med. 2017 Dec 19. doi: 10.1097/RLU.0000000000001934.
    PubMed     Text format     Abstract available

  31. JOCHUMSEN MR, Gormsen LC, Nielsen GL
    68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake.
    Clin Nucl Med. 2018;43:117-119.
    PubMed     Text format     Abstract available

  32. FRANKL J, Eshghi N, Lundeen TF, Kuo PH, et al
    Artifactual Hepatic Metastasis on FDG PET/CT Secondary to Cryoablation for Adrenal Metastasis.
    Clin Nucl Med. 2017 Dec 11. doi: 10.1097/RLU.0000000000001917.
    PubMed     Text format     Abstract available


    Eur Respir J

  33. MIKESCH JH, Schwammbach D, Hartmann W, Schmidt LH, et al
    Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer.
    Eur Respir J. 2018 May 31. pii: 13993003.01637-2017.
    PubMed     Text format     Abstract available

  34. SCHEERENS C, Beernaert K, Pype P, Cohen J, et al
    Comparing the use and timing of palliative care services in COPD and lung cancer: a population-based survey.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  35. SANDRI BJ, Kaplan A, Hodgson SW, Peterson M, et al
    Multi-Omic Molecular Profiling of Lung Cancer in Chronic Obstructive Pulmonary Disease.
    Eur Respir J. 2018 May 24. pii: 13993003.02665-2017.
    PubMed     Text format     Abstract available


    Int J Oncol

  36. LIU DH, An M, Bao BL, Ren F, et al
    Nicotine inhibits CD24 expression in Lewis lung carcinoma cells by upregulation of RAS expression.
    Int J Oncol. 2018 May 22. doi: 10.3892/ijo.2018.4415.
    PubMed     Text format     Abstract available

  37. ZHANG W, Cai X, Yu J, Lu X, et al
    Exosome-mediated transfer of lncRNA RP11838N2.4 promotes erlotinib resistance in non-small cell lung cancer.
    Int J Oncol. 2018 May 17. doi: 10.3892/ijo.2018.4412.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  38. ZHU Y, Tang K, Zhao F, Zang Y, et al
    End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.
    J Cancer Res Clin Oncol. 2018 May 29. pii: 10.1007/s00432-018-2673.
    PubMed     Text format     Abstract available

  39. XU J, Zhao X, He D, Wang J, et al
    Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    J Cancer Res Clin Oncol. 2018 May 24. pii: 10.1007/s00432-018-2668.
    PubMed     Text format     Abstract available


    J Clin Oncol

  40. SOLOMON BJ, Kim DW, Wu YL, Nakagawa K, et al
    Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  41. TSENG D, Padda SK, Wakelee HA
    Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:741-744.
    PubMed     Text format    

  42. BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
    Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    J Thorac Oncol. 2018;13:748-751.
    PubMed     Text format    

  43. WU CK, Kao SJ, Lai HC
    Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
    J Thorac Oncol. 2018;13:e103-e105.
    PubMed     Text format    

  44. WOZNIAK AJ, Schwartz AG
    Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
    J Thorac Oncol. 2018;13:e106-e107.
    PubMed     Text format    

  45. HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
    Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
    J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
    PubMed     Text format     Abstract available

  46. GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
    Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
    PubMed     Text format     Abstract available

  47. MASCALCHI M, Sali L
    Risk of Second Lung Cancer in ITALUNG LDCT Screening.
    J Thorac Oncol. 2018;13:e105-e106.
    PubMed     Text format    


    Lung Cancer

  48. BRAILLON A
    Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
    PubMed     Text format    


    Lung Cancer (Auckl)

  49. PARIKH AR, Ali SM, Schrock AB, Albacker LA, et al
    Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
    Lung Cancer (Auckl). 2018;9:45-47.
    PubMed     Text format     Abstract available


    Mol Carcinog

  50. LI Z, Fan J, Li N, Zhu M, et al
    Fine mapping in TERT-CLPTM1L region identified three independent lung cancer susceptibility signals: a large-scale multi-ethnic population study.
    Mol Carcinog. 2018 May 29. doi: 10.1002/mc.22843.
    PubMed     Text format     Abstract available


    N Engl J Med

  51. SCHILLER JH
    A New Standard of Care for Advanced Lung Cancer.
    N Engl J Med. 2018;378:2135-2137.
    PubMed     Text format    


    Nat Med

  52. MAINARDI S, Mulero-Sanchez A, Prahallad A, Germano G, et al
    SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Nat Med. 2018 May 28. pii: 10.1038/s41591-018-0023.
    PubMed     Text format     Abstract available


    Oncol Rep

  53. SATAR NA, Fakiruddin KS, Lim MN, Mok PL, et al
    Novel triplepositive markers identified in human nonsmall cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics.
    Oncol Rep. 2018 May 24. doi: 10.3892/or.2018.6461.
    PubMed     Text format     Abstract available

  54. XU G, Du J, Wang F, Zhang F, et al
    RAD52 motifcontaining protein 1 promotes nonsmall cell lung cancer cell proliferation and survival via cell cycle regulation.
    Oncol Rep. 2018 May 23. doi: 10.3892/or.2018.6459.
    PubMed     Text format     Abstract available

  55. CHEN T, Li B, Xu Y, Meng S, et al
    Luteolin reduces cancerinduced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
    Oncol Rep. 2018 May 21. doi: 10.3892/or.2018.6453.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  56. HANEY S, Konen J, Marcus AI, Bazhenov M, et al
    The complex ecosystem in non small cell lung cancer invasion.
    PLoS Comput Biol. 2018;14:e1006131.
    PubMed     Text format     Abstract available


    PLoS One

  57. ZHANG X, Nakajima T, Kim M, Yamaguchi A, et al
    Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model.
    PLoS One. 2018;13:e0198224.
    PubMed     Text format     Abstract available

  58. WALTER RFH, Rozynek P, Casjens S, Werner R, et al
    Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    PLoS One. 2018;13:e0195716.
    PubMed     Text format     Abstract available

  59. KIM KI, Jun JH, Baek H, Kim JH, et al
    Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0198015.
    PubMed     Text format     Abstract available

  60. GU L, Wang Z, Zuo J, Li H, et al
    Prognostic significance of NF-kappaB expression in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2018;13:e0198223.
    PubMed     Text format     Abstract available

  61. CHORNER PM, Moorehead RA
    A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.
    PLoS One. 2018;13:e0193344.
    PubMed     Text format     Abstract available

  62. KIM H, Kwon HJ, Park SY, Park Y, et al
    Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    PLoS One. 2018;13:e0198634.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  63. LEITHNER K, Triebl A, Trotzmuller M, Hinteregger B, et al
    The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells.
    Proc Natl Acad Sci U S A. 2018 May 29. pii: 1719871115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: